2Fujii M, Kochi M, Mochizuki F. Significance of neoadjuvant emotherapy for gastric cancer [J]. Gall To Kagaku Ryoho,2000,27 ( 11 ) : 2028-2032.
3Elliot NE, Marcus SG, Potmcsil M, et al. Neoadjuvant chemotherapy with CPT211and cisplatin downstages locally advanced gastric cancer [J ]. Gastrointest Surg, 2002,6 ( 2 ) : 212 -223.
4Macdonald JS, Smalley SR, Benedetti J,et al. Chemora-diotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junc-tion[ J J. N Engl J Med,2001,345 (10) :725-730.
5Wilke H, Preusser P, Fink U ,et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase Ⅱ study with etoposide, doxorubicin, and cisplatin [ J ]. J Clin Oncol, 1989,7(9) :1318.
6Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy[ J]. Ann Surg Oncol, 2002,9 (4) : 394-400.
7Thirion PG, Michiels S, Le Maitre A, et al. Ilndividual patient data- based meta-analysis assessing pre-operafive chemotherapy in resectable oesophageal carcinoma[J]. Journal of Clinical Onedogy,2007, 25(18S) :4512.
8Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [ J ]. N Engl J Med,2007,357 ( 18 ) : 1810-1820.
